CN112225821A - 一种具有抗肿瘤作用的多肽及其应用 - Google Patents
一种具有抗肿瘤作用的多肽及其应用 Download PDFInfo
- Publication number
- CN112225821A CN112225821A CN202011130905.2A CN202011130905A CN112225821A CN 112225821 A CN112225821 A CN 112225821A CN 202011130905 A CN202011130905 A CN 202011130905A CN 112225821 A CN112225821 A CN 112225821A
- Authority
- CN
- China
- Prior art keywords
- beta
- polypeptide
- riii
- tat
- migration
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 41
- 229920001184 polypeptide Polymers 0.000 title claims abstract description 40
- 102000004196 processed proteins & peptides Human genes 0.000 title claims abstract description 40
- 230000000259 anti-tumor effect Effects 0.000 title claims abstract description 8
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 17
- 210000004881 tumor cell Anatomy 0.000 claims abstract description 11
- 150000007523 nucleic acids Chemical class 0.000 claims description 10
- 239000003814 drug Substances 0.000 claims description 9
- 108020004707 nucleic acids Proteins 0.000 claims description 9
- 102000039446 nucleic acids Human genes 0.000 claims description 9
- 230000002401 inhibitory effect Effects 0.000 claims description 8
- 230000004709 cell invasion Effects 0.000 claims description 7
- 230000012292 cell migration Effects 0.000 claims description 7
- 206010060862 Prostate cancer Diseases 0.000 claims description 4
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 4
- 238000002347 injection Methods 0.000 claims description 4
- 239000007924 injection Substances 0.000 claims description 4
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 3
- 241000894006 Bacteria Species 0.000 claims description 2
- 239000004480 active ingredient Substances 0.000 claims description 2
- 238000010255 intramuscular injection Methods 0.000 claims description 2
- 239000007927 intramuscular injection Substances 0.000 claims description 2
- 239000007928 intraperitoneal injection Substances 0.000 claims description 2
- 230000002601 intratumoral effect Effects 0.000 claims description 2
- 238000010253 intravenous injection Methods 0.000 claims description 2
- 238000010254 subcutaneous injection Methods 0.000 claims description 2
- 239000007929 subcutaneous injection Substances 0.000 claims description 2
- 239000013598 vector Substances 0.000 claims description 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 210000000481 breast Anatomy 0.000 claims 1
- 210000004072 lung Anatomy 0.000 claims 1
- 230000002611 ovarian Effects 0.000 claims 1
- 102000007379 beta-Arrestin 2 Human genes 0.000 abstract description 17
- 108010032967 beta-Arrestin 2 Proteins 0.000 abstract description 17
- 230000005012 migration Effects 0.000 abstract description 16
- 238000013508 migration Methods 0.000 abstract description 16
- 201000011510 cancer Diseases 0.000 abstract description 13
- 230000009545 invasion Effects 0.000 abstract description 12
- 230000003993 interaction Effects 0.000 abstract description 7
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract description 4
- 108091005735 TGF-beta receptors Proteins 0.000 abstract 1
- 102000016715 Transforming Growth Factor beta Receptors Human genes 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 34
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 12
- 239000012528 membrane Substances 0.000 description 10
- 206010033128 Ovarian cancer Diseases 0.000 description 9
- 206010061535 Ovarian neoplasm Diseases 0.000 description 9
- 206010038389 Renal cancer Diseases 0.000 description 9
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
- 230000005764 inhibitory process Effects 0.000 description 8
- 208000008839 Kidney Neoplasms Diseases 0.000 description 7
- 201000010982 kidney cancer Diseases 0.000 description 7
- 239000012980 RPMI-1640 medium Substances 0.000 description 6
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 6
- 238000012258 culturing Methods 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 4
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 4
- 239000006285 cell suspension Substances 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 108010082117 matrigel Proteins 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 239000008055 phosphate buffer solution Substances 0.000 description 4
- 229920000515 polycarbonate Polymers 0.000 description 4
- 239000004417 polycarbonate Substances 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 206010006187 Breast cancer Diseases 0.000 description 3
- 208000026310 Breast neoplasm Diseases 0.000 description 3
- 108020004414 DNA Proteins 0.000 description 3
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 3
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 3
- 125000000539 amino acid group Chemical group 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 201000005202 lung cancer Diseases 0.000 description 3
- 208000020816 lung neoplasm Diseases 0.000 description 3
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 3
- 201000002528 pancreatic cancer Diseases 0.000 description 3
- 208000008443 pancreatic carcinoma Diseases 0.000 description 3
- 230000000149 penetrating effect Effects 0.000 description 3
- 238000011144 upstream manufacturing Methods 0.000 description 3
- 229920000742 Cotton Polymers 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 208000006265 Renal cell carcinoma Diseases 0.000 description 2
- 102100021669 Stromal cell-derived factor 1 Human genes 0.000 description 2
- 101710088580 Stromal cell-derived factor 1 Proteins 0.000 description 2
- 241000723873 Tobacco mosaic virus Species 0.000 description 2
- 102000004142 Trypsin Human genes 0.000 description 2
- 108090000631 Trypsin Proteins 0.000 description 2
- 230000005856 abnormality Effects 0.000 description 2
- 108010079292 betaglycan Proteins 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 238000007806 cell migration and invasion assay Methods 0.000 description 2
- 230000009087 cell motility Effects 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 210000004748 cultured cell Anatomy 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 238000001976 enzyme digestion Methods 0.000 description 2
- 108020001507 fusion proteins Proteins 0.000 description 2
- 102000037865 fusion proteins Human genes 0.000 description 2
- 238000009650 gentamicin protection assay Methods 0.000 description 2
- 238000011081 inoculation Methods 0.000 description 2
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 2
- 229910052759 nickel Inorganic materials 0.000 description 2
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 2
- 201000010174 renal carcinoma Diseases 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 239000012588 trypsin Substances 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 102000007469 Actins Human genes 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- CBCCCLMNOBLBSC-XVYDVKMFSA-N Ala-His-Ser Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CO)C(O)=O CBCCCLMNOBLBSC-XVYDVKMFSA-N 0.000 description 1
- MSWSRLGNLKHDEI-ACZMJKKPSA-N Ala-Ser-Glu Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(O)=O)C(O)=O MSWSRLGNLKHDEI-ACZMJKKPSA-N 0.000 description 1
- UISQLSIBJKEJSS-GUBZILKMSA-N Arg-Arg-Ser Chemical compound NC(N)=NCCC[C@H](N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CO)C(O)=O UISQLSIBJKEJSS-GUBZILKMSA-N 0.000 description 1
- KBBKCNHWCDJPGN-GUBZILKMSA-N Arg-Gln-Gln Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(O)=O KBBKCNHWCDJPGN-GUBZILKMSA-N 0.000 description 1
- 101710167800 Capsid assembly scaffolding protein Proteins 0.000 description 1
- 102000011068 Cdc42 Human genes 0.000 description 1
- 108050001278 Cdc42 Proteins 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 241001198387 Escherichia coli BL21(DE3) Species 0.000 description 1
- MDOBWSFNSNPENN-PMVVWTBXSA-N His-Thr-Gly Chemical compound [H]N[C@@H](CC1=CNC=N1)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(O)=O MDOBWSFNSNPENN-PMVVWTBXSA-N 0.000 description 1
- 108700000788 Human immunodeficiency virus 1 tat peptide (47-57) Proteins 0.000 description 1
- LBRCLQMZAHRTLV-ZKWXMUAHSA-N Ile-Gly-Ser Chemical compound CC[C@H](C)[C@H](N)C(=O)NCC(=O)N[C@@H](CO)C(O)=O LBRCLQMZAHRTLV-ZKWXMUAHSA-N 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 102000016943 Muramidase Human genes 0.000 description 1
- 108010014251 Muramidase Proteins 0.000 description 1
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 108010033276 Peptide Fragments Proteins 0.000 description 1
- 102000007079 Peptide Fragments Human genes 0.000 description 1
- 101710130420 Probable capsid assembly scaffolding protein Proteins 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 101710204410 Scaffold protein Proteins 0.000 description 1
- DINQYZRMXGWWTG-GUBZILKMSA-N Ser-Pro-Pro Chemical compound OC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(O)=O)CCC1 DINQYZRMXGWWTG-GUBZILKMSA-N 0.000 description 1
- HHJFMHQYEAAOBM-ZLUOBGJFSA-N Ser-Ser-Ala Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(O)=O HHJFMHQYEAAOBM-ZLUOBGJFSA-N 0.000 description 1
- XQJCEKXQUJQNNK-ZLUOBGJFSA-N Ser-Ser-Ser Chemical compound OC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(O)=O XQJCEKXQUJQNNK-ZLUOBGJFSA-N 0.000 description 1
- TYVAWPFQYFPSBR-BFHQHQDPSA-N Thr-Ala-Gly Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C)C(=O)NCC(O)=O TYVAWPFQYFPSBR-BFHQHQDPSA-N 0.000 description 1
- LIXBDERDAGNVAV-XKBZYTNZSA-N Thr-Gln-Ser Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(O)=O LIXBDERDAGNVAV-XKBZYTNZSA-N 0.000 description 1
- DNCUODYZAMHLCV-XGEHTFHBSA-N Thr-Pro-Cys Chemical compound C[C@H]([C@@H](C(=O)N1CCC[C@H]1C(=O)N[C@@H](CS)C(=O)O)N)O DNCUODYZAMHLCV-XGEHTFHBSA-N 0.000 description 1
- MIKHIIQMRFYVOR-RCWTZXSCSA-N Val-Pro-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@@H]1CCCN1C(=O)[C@H](C(C)C)N)O MIKHIIQMRFYVOR-RCWTZXSCSA-N 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 238000003766 bioinformatics method Methods 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 210000004292 cytoskeleton Anatomy 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 239000012149 elution buffer Substances 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 229960000274 lysozyme Drugs 0.000 description 1
- 239000004325 lysozyme Substances 0.000 description 1
- 235000010335 lysozyme Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 239000002808 molecular sieve Substances 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 238000001742 protein purification Methods 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 238000007634 remodeling Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 108010048818 seryl-histidine Proteins 0.000 description 1
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 230000007998 vessel formation Effects 0.000 description 1
- 239000011534 wash buffer Substances 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Toxicology (AREA)
- Cell Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Oncology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
Claims (7)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202011130905.2A CN112225821B (zh) | 2020-10-21 | 2020-10-21 | 一种具有抗肿瘤作用的多肽及其应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202011130905.2A CN112225821B (zh) | 2020-10-21 | 2020-10-21 | 一种具有抗肿瘤作用的多肽及其应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN112225821A true CN112225821A (zh) | 2021-01-15 |
CN112225821B CN112225821B (zh) | 2021-05-21 |
Family
ID=74118688
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202011130905.2A Active CN112225821B (zh) | 2020-10-21 | 2020-10-21 | 一种具有抗肿瘤作用的多肽及其应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN112225821B (zh) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114249837A (zh) * | 2021-12-28 | 2022-03-29 | 徐州医科大学 | 一种多肽、及其制备方法和应用 |
CN114835776A (zh) * | 2022-04-08 | 2022-08-02 | 陕西师范大学 | 一种靶向Smad4/PELO相互作用的抵抗肿瘤转移小分子多肽及应用 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20040018598A (ko) * | 2002-08-23 | 2004-03-04 | 코웰창업투자(주) | Tat-PTEN 융합 단백질, 이의 제조 방법 및 용도 |
CN101711874A (zh) * | 2008-10-08 | 2010-05-26 | 广州暨南大学医药生物技术研究开发中心 | 穿膜肽Tat介导的生长因子在透皮转运中的应用 |
CN102089320B (zh) * | 2008-01-24 | 2015-11-25 | 埃斯佩兰斯医药公司 | 溶解结构域融合构建体及其制备和使用方法 |
WO2016077618A1 (en) * | 2014-11-12 | 2016-05-19 | University Of Mississippi Medical Center | Kidney-targeted drug delivery systems |
WO2019241625A9 (en) * | 2018-06-15 | 2020-07-02 | Acceleron Pharma Inc. | Bi-and tri-functional fusion proteins and uses thereof |
-
2020
- 2020-10-21 CN CN202011130905.2A patent/CN112225821B/zh active Active
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20040018598A (ko) * | 2002-08-23 | 2004-03-04 | 코웰창업투자(주) | Tat-PTEN 융합 단백질, 이의 제조 방법 및 용도 |
CN102089320B (zh) * | 2008-01-24 | 2015-11-25 | 埃斯佩兰斯医药公司 | 溶解结构域融合构建体及其制备和使用方法 |
CN101711874A (zh) * | 2008-10-08 | 2010-05-26 | 广州暨南大学医药生物技术研究开发中心 | 穿膜肽Tat介导的生长因子在透皮转运中的应用 |
WO2016077618A1 (en) * | 2014-11-12 | 2016-05-19 | University Of Mississippi Medical Center | Kidney-targeted drug delivery systems |
WO2019241625A9 (en) * | 2018-06-15 | 2020-07-02 | Acceleron Pharma Inc. | Bi-and tri-functional fusion proteins and uses thereof |
Non-Patent Citations (8)
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114249837A (zh) * | 2021-12-28 | 2022-03-29 | 徐州医科大学 | 一种多肽、及其制备方法和应用 |
CN114249837B (zh) * | 2021-12-28 | 2023-10-20 | 徐州医科大学 | 一种多肽、及其制备方法和应用 |
CN114835776A (zh) * | 2022-04-08 | 2022-08-02 | 陕西师范大学 | 一种靶向Smad4/PELO相互作用的抵抗肿瘤转移小分子多肽及应用 |
CN114835776B (zh) * | 2022-04-08 | 2023-09-01 | 陕西师范大学 | 一种靶向Smad4/PELO相互作用的抵抗肿瘤转移小分子多肽及应用 |
Also Published As
Publication number | Publication date |
---|---|
CN112225821B (zh) | 2021-05-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN112225821B (zh) | 一种具有抗肿瘤作用的多肽及其应用 | |
CN112794918A (zh) | 针对新型冠状病毒的人ACE2改造蛋白、ACE2-hFc类抗体蛋白 | |
CN110023333B (zh) | 高亲和力的可溶性pd-1分子 | |
JP2016520053A (ja) | 腫瘍微小環境における血管再生の抑制及び適応免疫応答の活性化を有する二機能の融合タンパク質及びその遺伝子並びに使用 | |
AU2012306826B2 (en) | Endostatin mutants with mutations at ATP binding sites | |
CN114292338A (zh) | 一种融合蛋白及其制备司美格鲁肽中间体多肽的方法 | |
CN110590961B (zh) | 一种具有抗癌作用的多肽及其应用 | |
US20240002472A1 (en) | Ulinastatin polypeptides | |
CN109485718B (zh) | 一种新型干扰素α及其制备方法、组合物和用途 | |
KR101263424B1 (ko) | 세포투과성 엔도스타틴 재조합 단백질, 이를 코딩하는 폴리뉴클레오티드 및 이를 유효성분으로 함유하는 항암 조성물 | |
JP2729712B2 (ja) | 機能性ポリペプチド | |
WO2021136521A1 (zh) | 多肽及其应用 | |
KR101651330B1 (ko) | 세포투과성이 우수한 tat-a20 융합단백질의 제조방법 및 이의 용도 | |
KR20080026085A (ko) | 곤충세포에서 제조한 재조합 e-셀렉틴 | |
CN109652400A (zh) | 抗癌药物精氨酸脱亚胺酶半衰期的分子改造方法及突变株 | |
CN109485719B (zh) | 一种新型干扰素α1及其制备方法、组合物和用途 | |
KR20110106333A (ko) | 세포투과성 p53 재조합 단백질, 이를 코딩하는 폴리뉴클레오티드 및 이를 유효성분으로 함유하는 항암 조성물 | |
CN114249837B (zh) | 一种多肽、及其制备方法和应用 | |
CN116425888A (zh) | 一种多肽tat-v2r1c及其应用 | |
CN114262384B (zh) | 一种多肽及其保护心肌缺血/再灌注损伤作用的应用 | |
CA2343719C (en) | New human hepatoma-derived growth factor encoding sequence and polypeptide encoded by such dna sequence and producing method thereof | |
CN109467597A (zh) | 一种新型干扰素及其制备方法、组合物和用途 | |
CN102718846A (zh) | 活性增强的sec2突变蛋白及编码基因与制备和应用 | |
CN112239508A (zh) | 一种具有抑制肥胖作用的多肽及其应用 | |
JPH0371111B2 (zh) |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20221130 Address after: 471,000 902, Building 7, West Block of Luoyang Zhengda International CPL.Citizen Center, Jinchengzhai Street, Luolong District, Luoyang City, Henan Province Patentee after: Jingcheng (Henan) Intellectual Property Service Co.,Ltd. Address before: 221004 No.209 Tongshan Road, Yunlong District, Xuzhou City, Jiangsu Province Patentee before: XUZHOU MEDICAL University |
|
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20221221 Address after: 10000018005, Unit 1, Floor 15, Building 2, Yard 3, Changtong Road, Chaoyang District, Beijing Patentee after: CHUANGKESHANGMENG CO.,LTD. Address before: 471,000 902, Building 7, West Block of Luoyang Zhengda International CPL.Citizen Center, Jinchengzhai Street, Luolong District, Luoyang City, Henan Province Patentee before: Jingcheng (Henan) Intellectual Property Service Co.,Ltd. |
|
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20240425 Address after: 066000 Road East, 30 meters south of the intersection of Sanfu Road and Beigui Third Street in Funing District, Qinhuangdao City, Hebei Province, China Patentee after: Qinhuangdao Fuyingguan Technology Co.,Ltd. Country or region after: China Address before: 10000018005, Unit 1, Floor 15, Building 2, Yard 3, Changtong Road, Chaoyang District, Beijing Patentee before: CHUANGKESHANGMENG CO.,LTD. Country or region before: China |